RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
India’s Cipla formed a $30 million joint venture with Jiangsu Acebright Pharma to bring Cipla’s generic drugs to the China market. Cipla will contribute 80% of the JV’s capital and own 80% of the JV, which will also establish a manufacturing facility for Cipla’s respiratory products in China. Cipla, which is active in many global markets, is India’s third largest pharma. One month ago, in a similar India-China agreement, Sun Pharma of India forged a deal with China Medical System Holdings to develop and commercialize two drugs in Greater China. Source: China Biotoday
